University of California Berkeley seal E. O. Lawrence Berkeley National Laboratory seal
The Carcinogenic Potency Project

Ethylene thiourea (CAS 96-45-7)
SMILES, InChI and Structure are below.
Rats and Mice: Cancer Test Summary
Rat Target Sites Mouse Target Sites TD50 (mg/kg/day)
Male Female Male Female Rat Mouse
liv(B) thy liv(B) thy liv pit thy liv pit thy 8.13m,v 23.5m

Key to the Table Above

Positivity: For each chemical with a positive (carcinogenic) experiment in the Carcinogenic Potency Database (CPDB), results are included on carcinogenic potency (TD50) in each species and target sites in males and females. Positivity is determined by an author’s opinion in a published paper. If all experimental results in the CDPB are negative in a sex-species group, “no positive” appears. If the CPDB has no experiments in the sex-species group, “no test” appears. The summary presents the strongest evidence of carcinogenicity in each group. If there are both positive and negative experiments in a sex-species, the negative results are ignored in this Summary Table.
Target Site Codes:   liv = liver. pit = pituitary gland. thy = thyroid gland. (B) = experimental results were reported only for both sexes together. Target sites are listed if any author of published experimental results concluded that tumors were induced in that organ by the test agent. If there is more than one positive experiment in a sex-species, target sites listed may be from more than one experiment, e.g. if liver and lung are both listed, then liver may have been a target in one experiment and lung in another.
TD50: Our standardized measure of carcinogenic potency, TD50, is the daily dose rate in mg/kg body weight/day to induce tumors in half of test animals that would have remained tumor-free at zero dose. Whenever there is more than one positive experiment in a species, the reported TD50 value is a Harmonic Mean calculated using the TD50 value from the most potent target site in each positive experiment.
Superscripts:   m = There is more than one positive experiment in the species, and TD50 values from each positive experiment are used in the calculation of the reported Harmonic mean of TD50. v = Variation is greater than ten-fold among statistically significant (two-tailed p<0.1) TD50 values from different positive experiments.

The Carcinogenic Potency Database (CPDB) is a unique and widely used international resource of the results of 6540 chronic, long-term animal cancer tests on 1547 chemicals. The CPDB provides easy access to the bioassay literature, with qualitative and quantitative analyses of both positive and negative experiments that have been published over the past 50 years in the general literature through 2001 and by the National Cancer Institute/National Toxicology Program through 2004. The CPDB standardizes the diverse literature of cancer bioassays that vary widely in protocol, histopathological examination and nomenclature, and in the published author’s choices of what information to provide in their papers. Results are reported in the CPDB for tests in rats, mice, hamsters, dogs, and nonhuman primates.

For each experiment, information is included on species, strain, and sex of test animal; features of experimental protocol such as route of administration, duration of dosing, dose level(s) in mg/kg body weight/day, and duration of experiment; experimental results are provided on target organ, tumor type, and tumor incidence; carcinogenic potency (TD50) and its statistical significance; shape of the dose-response, author’s opinion as to carcinogenicity, and literature citation.

Only tests with dosing for at least ¼ the standard lifespan of the species and experiment length at least ½ the lifespan are included in the CPDB. Only routes of administration with whole body exposure are included. Doses are standardized, average dose rates in mg/kg/day. A description of methods used in the CPDB to standardize the diverse literature of animal cancer tests is presented for: 1) Criteria for inclusion of experiments 2) Standardization of average daily dose levels and 3) TD50 estimation for a standard lifespan. See Methods for other details.

TD50 provides a standardized quantitative measure that can be used for comparisons and analyses of many issues in carcinogenesis. The range of TD50 values across chemicals that are rodent carcinogens is more than 100 million-fold. More than half the chemicals tested are positive in at least one experiment.

A plot of all results on each experiment in the CPDB for this chemical is presented below. These results are the source information for the Cancer Test Summary table above.

Ethylene thiourea: All Experiments and Citations in CPDB
The definition of each code in the plot below will appear in a pop-up window when the field name in the header line is clicked, e.g., Strain, Site, Path. Each numbered line starts a new experiment and reports protocol information in black. Average daily dose-rates per kg body weight per day are in green. Remaining lines report experimental results in blue.
Abbreviations of fields in header line: # = the line number in the plot of all CPDB chemicals; Xpo = duration of dosing; Xpt = duration of experiment; Site = tissue; Path = tumor type; DR = dose-response; AuOp = author’s opinion about carcinogenicity; LoConf, UpConf = confidence limits (99%) on TD50; Inc = tumor incidence for each dose group.
See Guide to reading the plot for details on each field, using an example of one experiment.
See Help to improve readability, or to fit the plot onto the screen or a printed page. 



Chemical (Synonym) CAS
# Species Sex Strain Route Xpo+Xpt PaperNum        0 Dose  1 Dose 2 Dose  3 Dose          Literature Reference or NCI/NTP:Site Path
Site Path Notes   TD50  DR Pval    AuOp LoConf UpConf   Cntrl   1 Inc  2 Inc   3 Inc                                                        Brkly Code


ETHYLENE THIOUREA  (ETU) 96-45-7
2748 M f b6c eat 25m25 TR388 :                       0    42.9mg  130.mg
 liv MXA        19.9mg \ P<.0005 c  12.7mg 38.1mg   4/50   44/50  (48/50)                                             liv:hpa,hpc.
 MXB MXB        26.6mg \ P<.0005    14.5mg 96.7mg  14/50   47/50  (48/50)                   liv:hpa,hpc; pit:pda,pdc; thy:fca,fcc. C
 liv hpa        30.5mg \ P<.0005 c  19.1mg 59.9mg   2/50   33/50  (14/50)
 liv hpc        39.7mg * P<.0005 c  28.4mg 62.9mg   2/50   29/50   47/50
 thy MXA        82.0mg / P<.0005 c  55.5mg 128.mg   0/50    2/50   38/50                                              thy:fca,fcc.
 thy fca        90.9mg / P<.0005 c  60.6mg 144.mg   0/50    2/50   35/50
 pit pda        147.mg * P<.003  c  74.6mg 973.mg  10/50   19/50   26/50
 pit MXA        155.mg * P<.005  c  76.7mg 1.57gm  11/50   19/50   26/50                                              pit:pda,pdc.
 thy fcc        546.mg * P<.0005 c  246.mg 1.69gm   0/50    0/50    8/50
 TBA MXB        120.mg * P<.08      46.2mg n.s.s.  36/50   49/50   48/50
 liv MXB        19.9mg \ P<.0005    12.7mg 38.1mg   4/50   44/50  (48/50)                                         liv:hpa,hpc,nnd.
 lun MXB        641.mg \ P<.7       93.4mg n.s.s.   5/50    8/50   (0/50)                                             lun:a/a,a/c.
2749 M f b6c orl 81w81 1141                          0    88.8mg                                                Innes;ntis,1968/1969
 liv hpt evx    noTD50   P<.0005    n.s.s. 20.7mg   0/16   18/18
 lun ade evx    203.mg   P<.05      61.1mg n.s.s.   0/16    3/18
 tba mix evx    noTD50   P<.0005    n.s.s. 20.7mg   0/16   18/18
2750 M m b6c eat 25m25 TR388 :                       0    39.6mg  120.mg
 liv MXA        54.1mg * P<.0005 c  30.6mg 158.mg  20/50   32/50   46/50                                              liv:hpa,hpc.
 MXB MXB        54.1mg * P<.0005    30.6mg 159.mg  21/50   32/50   47/50                        liv:hpa,hpc; pit:pda; thy:fca,fcc. C
 liv hpc        54.6mg / P<.0005 c  33.5mg 116.mg  13/50   19/50   45/50
 thy MXA        97.1mg / P<.0005 c  60.7mg 172.mg   1/50    1/50   29/50                                              thy:fca,fcc.
 thy fca        112.mg / P<.0005 c  69.6mg 194.mg   0/50    1/50   26/50
 pit pda        387.mg * P<.0005 c  173.mg 1.20gm   0/50    0/50    8/50
 thy fcc        730.mg * P<.04   c  246.mg n.s.s.   1/50    0/50    5/50
 MXA hem        840.mg * P<.03      284.mg n.s.s.   0/50    1/50    3/50                                ear:hem; hea:hem; liv:hem. S
 TBA MXB        89.2mg * P<.03      38.6mg n.s.s.  35/50   40/50   47/50
 liv MXB        54.1mg * P<.0005    30.6mg 158.mg  20/50   32/50   46/50                                          liv:hpa,hpc,nnd.
 lun MXB        532.mg * P<.3       156.mg n.s.s.   5/50    6/50    8/50                                              lun:a/a,a/c.
2751 M m b6c orl 82w82 1141                          0    82.5mg                                                Innes;ntis,1968/1969
 liv hpt evx    16.9mg   P<.0005 +  7.63mg 40.5mg   0/16   14/16
 lun ade evx    545.mg   P<.3       88.7mg n.s.s.   0/16    1/16
 tba mix evx    16.9mg   P<.0005    7.63mg 40.5mg   0/16   14/16
2752 M f b6a orl 81w81 1141                          0    88.8mg
 liv hpt evx    44.7mg   P<.0005    20.4mg 124.mg   0/17    9/16
 lun ade evx    no dre   P=1.       178.mg n.s.s.   1/17    0/16
 tba mix evx    29.3mg   P<.0005    13.2mg 99.9mg   2/17   12/16
2753 M m b6a orl 81w81 1141                          0    82.6mg
 liv hpt evx    noTD50   P<.0005    n.s.s. 20.0mg   1/18   18/18
 lun ade evx    no dre   P=1.       87.7mg n.s.s.   2/18    2/18
 tba mix evx    noTD50   P<.0005    n.s.s. 21.8mg   3/18   18/18
2754 R f f34 eat 25m25 TR388 :                       0    4.15mg  12.5mg
 thy MXA        7.42mg / P<.0005 c  4.74mg 13.2mg   1/50    6/50   28/50                                              thy:fab,fca.
 thy MXA        7.42mg / P<.0005 c  4.64mg 14.2mg   3/50    7/50   30/50                                      thy:fab,fca,fcy,fdc.
 thy MXA        39.6mg / P<.02   c  15.9mg n.s.s.   2/50    1/50    8/50                                              thy:fcy,fdc.
 TBA MXB        24.6mg * P<.5       5.13mg n.s.s.  48/50   46/50   49/50
 liv MXB        no dre   P=1.       82.4mg n.s.s.   0/50    1/50    0/50                                          liv:hpa,hpc,nnd.
2755 R m f34 eat 25m25 TR388 :                       0    3.32mg  10.0mg
 thy MXA        3.16mg * P<.0005 c  2.08mg 5.23mg   1/50   12/50   37/50                                      thy:fab,fca,fcy,fdc.
 thy MXA        5.25mg * P<.0005 c  3.28mg 9.00mg   0/50    9/50   23/50                                              thy:fab,fca.
 thy MXA        5.50mg / P<.0005 c  3.29mg 10.4mg   1/50    3/50   26/50                                              thy:fcy,fdc.
 TBA MXB        17.8mg * P<.5       3.49mg n.s.s.  43/50   47/50   43/50
 liv MXB        186.mg * P<.2       30.3mg n.s.s.   0/50    0/50    1/50                                          liv:hpa,hpc,nnd.
2756 R b cdr eat 24m24 139                           0    .225mg  1.13mg  5.63mg  11.3mg  22.5mg         Graham;fctx,13,493-499;1975
 --- fbs e      13.2mg Z P<.003     5.00mg 75.7mg   0/72    0/75    5/73   (4/73    5/69    3/70)
 thy mix e      16.6mg Z P<.0005 +  12.5mg 22.9mg   2/72    2/75    1/73    2/73   16/69   62/70
 thy ade e      33.9mg Z P<.0005 +  20.0mg 70.6mg   2/72    0/75    5/73    1/73   21/69   (3/70)
 liv hpt e      330.mg * P<.04   +  117.mg n.s.s.   1/72    1/75    1/73    2/73    1/69    5/70
 mgl adc e      no dre   P=1.       100.mg n.s.s.   2/72   14/75    4/73    2/73    5/69   (0/70)
 tba mix e      7.23mg * P<.0005    4.58mg 13.5mg  51/72   49/75   45/73   54/73   61/69   68/70
 tba mal e      13.4mg Z P<.0005    9.62mg 19.9mg  15/72   23/75   13/73   16/73   31/69   63/70
2757 R f cdr eat 18m24 141m                          0    6.56mg  13.1mg                 Ulland;jnci,49,583-584;1972/Weisburger 1981
 thy fcc j      39.8mg * P<.03   +  18.0mg n.s.s.   0/10    2/26    6/26
 thy ppc j      113.mg * P<.3    +  34.2mg n.s.s.   0/10    1/26    2/26
 liv hnd j      no dre   P=1.       59.4mg n.s.s.   0/10    1/26    0/26
2758 R m cdr eat 18m24 141m                          0    5.25mg  10.5mg
 thy fcc j      12.8mg / P<.0005 +  7.21mg 28.7mg   0/10    2/26   15/26
 thy ppc j      90.5mg * P<.3    +  27.4mg n.s.s.   0/10    1/26    2/26
 liv hnd j      179.mg * P<.8       27.7mg n.s.s.   0/10    2/26    1/26
Mutagenicity in Salmonella: positive
SMILES Code for Ethylene thiourea: S=C1NCCN1
InChI Code for Ethylene thiourea: InChI=1/C3H6N2S/c6-3-4-1-2-5-3/h1-2H2,(H2,4,5,6)
Source for SMILES and InChI: USEPA Distributed Structure-Searchable Toxicity (DSSTox) Database
Chemical Structure for Ethylene thiourea: Chemical Structure
Source for structure: National Library of Medicine ChemIDPlus

See full CPDB Summary Table on 1547 chemicals. See Full CPDB for all results on 6540 experiments of 1547 chemicals.

A complete list of CPDB chemicals, which is searchable by name or by CAS number, is available here.

For a compendium of CPDB results organized by target organ, which lists all chemicals in each species that induced tumors in each of 35 organs, see Summary Table by Target Organ.

The CPDB is available in several formats that permit printing and downloading into spreadsheets and statistical databases.

  1. A plot of the CPDB presents results of 1547 experiments on 6540 chemicals in an easily readable format that has been used in publications of the CPDB.
  2. A Screen version plot for use on a single computer screen, with the same data.
  3. Excel version of the same data.
  4. Tab-separated versions of the same data, which can be easily read into databases.

A Supplementary Dataset gives details on dosing and survival for each experiment.

Relatively precise estimates of the lower confidence limit on the TD10 (LTD10) are readily calculated from the TD50 and its lower confidence limit, which are reported in the CPDB. For researchers and regulatory agencies interested in LTD10 values, we provide them in an Excel spreadsheet.

PDF versions of our publications of analyses using the CPDB are available, organized by year and by research topic.

Carcinogenic Potency Database Project (CPDB) Home Page
For more information about this Web Page, contact Specialized Information Services (support@leadscope.com).
Last updated: October 3, 2007


PDF documents are best viewed with the free Adobe® Reader http://get.adobe.com/reader
Excel documents are best viewed with the free Excel® Viewer http://www.microsoft.com/en-us/download/details.aspx?id=10